OncoSec Announces Presentation at Upcoming American Association for Cancer Research (AACR) Annual Meeting 2016

17 Mar, 2016, 06:00 ET from OncoSec Medical Incorporated

SAN DIEGO, March 17, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that new clinical data will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held on April 16-20, 2016 in New Orleans, LA.

This new data relates to the Company's Phase II monotherapy clinical study of its investigational intratumoral plasmid IL-12 with electroporation (IT-pIL12-EP) in patients with melanoma. After completing treatment with IT-pIL12-EP, a subset of patients subsequently received anti-PD-1/PD-L1 therapies. Patients with documented follow-up history and evaluable for anti-PD-1/PD-L1 response were included in this single-site retrospective analysis.

Details of the presentation are as follows:

  • Abstract Title: Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma (Abstract #CT134)
  • Session Title: Early Clinical Trials Evaluating Cell-based Checkpoint Inhibitors and Novel Immunotherapeutics
  • Date and Time: April 19, 2016 at 3:45 - 4:00 PM
  • Location: Room 343, Morial Convention Center

About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies for the treatment of cancer. The Company's investigational technology, ImmunoPulse™, is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as interleukin-12 (IL-12). In Phase I and II clinical trials, OncoSec's lead program, ImmunoPulse™ IL-12, demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. ImmunoPulse™ IL-12 is currently in Phase II development for several indications, including metastatic melanoma and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also seeking to identify and develop new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.

Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "will," "can," and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: uncertainties inherent in pre-clinical studies and clinical trials, such as the ability to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; our ability to raise additional funding necessary to fund continued operations; and the other factors discussed in OncoSec's filings with the Securities and Exchange Commission.

Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact Mary Marolla OncoSec Medical Incorporated 855-662-6732 media@oncosec.com

Photo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

 

SOURCE OncoSec Medical Incorporated



RELATED LINKS

http://www.oncosec.com